[HTML][HTML] A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway …
Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
[PDF][PDF] A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM …
S Perreault, V Larouche, U Tabori, C Hawkin, S Lippé… - 2019 - prism.ucalgary.ca
Background: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
S Perreault, V Larouche, U Tabori, C Hawkin… - BMC …, 2019 - search.proquest.com
Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
S Perreault, V Larouche, U Tabori, C Hawkin, S Lippé… - BMC Cancer, 2019 - go.gale.com
Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway
S Perreault, V Larouche, U Tabor, C Hawkin… - BMC …, 2019 - papyrus.bib.umontreal.ca
Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
S Perreault, V Larouche, U Tabori, C Hawkin, S Lippé… - 2019 - open.library.ubc.ca
Background: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
S Perreault, V Larouche, U Tabori, C Hawkin, S Lippé… - BMC Cancer, 2019 - pure.psu.edu
Background: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
[HTML][HTML] A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway …
S Perreault, V Larouche, U Tabori… - BMC …, 2019 - bmccancer.biomedcentral.com
Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to
50% will be refractory to conventional chemotherapy. It is now known that the majority of …
50% will be refractory to conventional chemotherapy. It is now known that the majority of …
[HTML][HTML] A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway …
S Perreault, V Larouche, U Tabori, C Hawkin… - BMC Cancer, 2019 - ncbi.nlm.nih.gov
Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
S Perreault, V Larouche, U Tabori, C Hawkin… - BMC Cancer, 2019 - europepmc.org
BACKGROUND: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …